New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates | Zendy

Amit Kaushik | Zendy; Nicole C. Ammerman | Zendy; Nicole Parrish | Zendy; Eric L. Nuermberger | Zendy

Open Access

New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics against Mycobacterium abscessus Complex Clinical Isolates

Author(s) -

Amit Kaushik,

Nicole C. Ammerman,

Nicole Parrish,

Eric L. Nuermberger

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00733-19

Subject(s) - antibiotics , microbiology and biotechnology , mycobacterium abscessus , in vitro , biology , avibactam , lactam , mycobacterium , bacteria , pseudomonas aeruginosa , chemistry , biochemistry , genetics , stereochemistry , ceftazidime

The new diazabicyclooctane-based β-lactamase inhibitors avibactam and relebactam improve thein vitro activity of β-lactam antibiotics against bacteria of theMycobacterium abscessus complex (MABC). Here, we evaluated thein vitro activities of two newer diazabicyclooctane-based β-lactamase inhibitors in clinical development, nacubactam and zidebactam, with β-lactams against clinical isolates of MABC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research